Abdera Therapeutics

High-grade neuroendocrine lung cancers move fast, and still lack effective long-term treatment options. Through our ROVEr™ platform, we’re advancing precision radiotherapeutics to deliver radioisotopes to tumor targets with high unmet need. Learn more: abderatx.com/pipeline/

As our science moves forward, so does the space around it. We recently opened our state-of-the-art #CMC development lab in San Francisco, adding advanced analytical, radiochemistry, conjugation, and characterization capabilities — built to accelerate our path to clinic. With ABD-147 and ABD-320 continuing to build momentum, every investment we make in our pipeline is a step toward new options for patients.

View the full list of speakers and register here: championsoncology.com/san-diego-symp…

This week, Abdera scientist Etienne Melese joins the @ChampionsOncol1 6th Symposium to share preclinical data from ABD-320. ABD-320 is a next-generation 5T4-targeted radiopharmaceutical, developed using our proprietary ROVEr™ platform to enable targeted delivery of Actinium-225 to solid tumors. Looking forward to advancing the conversation around our antibody-based radiotherapeutic pipeline & continued execution.

Cancer is a deeply personal journey, and no one should face it alone. On #WorldCancerDay, we stand with patients, families, and communities affected by cancer. At Abdera, we’re purpose-built to advance targeted radiopharmaceuticals with the goal of delivering meaningful impact to those who matter most: people living with cancer.

At #JPM26, we highlighted our progress and long-term vision in radiotherapeutics. With continued execution of ABD-147 and ABD-320, our growing pipeline underscores our focus on patients and the path ahead.

From clinical progress to what’s ahead, Abdera CEO Lori Lyons-Williams will provide an overview of the company and our pipeline of first-in-class radiotherapeutics, including ABD-147 and ABD-320, at #JPM26. Guided by our mission to develop precision radiopharmaceuticals with the potential to transform #cancer care, we look forward to sharing how we’re advancing these programs toward patients. Details: abderatx.com/press-releases…

Lung cancer remains the leading cause of cancer-related deaths in the U.S., but early screening can improve five-year survival rates to 65%. This #LungCancerAwarenessMonth, we recognize the importance of early detection, stand with those affected, & celebrate the progress being made to defeat this disease. At Abdera, we’re committed to advancing innovation in #radiotherapeutics to help change the future of #cancer care, & we’re with you every step of the way.

Abdera leadership will be participating in multiple investor conferences this November. We look forward to sharing how our proprietary ROVEr platform is driving the design and development of tunable precision #radiopharmaceuticals to bring new hope to people living with cancer.

Abdera CTO takes part in @WomenInBio this week to discuss the future of precision oncology and how new breakthroughs are reshaping #cancer treatment. Join Kawa as she represents Abdera’s vision for advancing targeted #radiotherapeutics. Learn more: community.womeninbio.org/events/view/sa…

We’re looking forward to next week’s Longwood Healthcare Leaders Boston CEO event, where CEO Lori Lyons-Williams will join industry leaders to share insights and drive conversations that matter for patients. Details below.

The Abdera team sends warm wishes to our team and community in Canada this Thanksgiving! May your holiday be filled with gratitude, connection, and the simple joys that make this season special.

Abdera CEO Lori Lyons-Williams will join a panel at the annual @LongwoodLeaders Boston CEO event this October to share her perspectives on navigating today’s regulatory landscape. We’re excited to collaborate with industry leaders, exchange insights, and advance biomedical innovation to accelerate the translation of discoveries into medicines that improve patient outcomes. To learn more, visit longwoodhealthcareleaders.com/bostonceo

#TeamAbdera is back at the @GO2forLungCancr annual Bay Area 5K walk! Events like these help the organization to provide one-on-one assistance, screening, & treatment navigation, while also funding the latest research to accelerate cures for #lungcancer. We're here to walk beside you through every step of your cancer journey.

At Abdera, we are committed to advancing groundbreaking #cancer therapies for those who need them most. This #WorldCancerResearchDay, we celebrate our research team’s relentless pursuit to tackle cancers with high unmet need. Innovation fuels progress, & progress fuels hope. Today, we invite you to honor the researchers, clinicians, & patients who make that progress possible.

Abdera’s Director of Supply Chain will join a panel discussion on designing for demand & process strategies to support scale-up of #radiotherapeutic manufacturing at the 3rd annual TRP #SupplyChain & Manufacturing Summit. We look forward to Gabe’s insights & the chance to share how Abdera is tackling the challenges of scaling innovative therapies to reach more patients.

This past week, #TeamAbdera joined forces with @2ndHarvest of Silicon Valley & @RMHBC in Vancouver to support the fight against hunger and build stronger communities. Our mission is to bring hope to families, whether by advancing new treatments for devastating diseases or by supporting local communities in times of need. We’re proud to stand with organizations that nourish, support, and uplift people when they need it most.

Details: businesswire.com/news/home/2025… Today, we presented initial data from our ongoing Phase 1 clinical trial of ABD-147 in patients with #SCLC & LCNEC that support continued dose escalation at the IASLC #WCLC25. We’re encouraged by these promising data, with ABD-147 demonstrating the potential of DLL3-targeted alpha #radiotherapy as a next-generation approach for SCLC and other DLL3-expressing tumors.

Abdera CEO Lori Lyons-Williams will be joining industry leaders at the Radiopharmaceuticals Venture, Innovation & Partnering Summit in Boston, MA, next month to discuss the future of this rapidly advancing field. At Abdera, we’re advancing precisely targeted radiopharmaceuticals to deliver meaningful impact for patients with #cancer, & we look forward to contributing to this important conversation. View the full program & register at oncologyvipsummit.com/radiopharmaceu…. Use code “OVP25SPK25” to save 25%.

Details: businesswire.com/news/home/2025… We will present initial pharmacokinetics, dosimetry & safety data from our ongoing first-in-human Phase 1 trial of ABD-147 at the @IASLC #WCLC2025. Abdera leadership will also participate in several investor conferences this September. We look forward to sharing how we harness our proprietary ROVEr platform to design and develop tunable precision radiopharmaceuticals for #cancer.